• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Cold Chain Packaging and Logistics

    How Artificial Intelligence and Machine Learning are Transforming the Life Sciences

    Challenges of Preparing Highly Potent Oral Products

    Bioprocessing Trends

    Sustainable Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    groninger Continues Growth in the US

    Catalent Bolsters Cell and Gene Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    What Does the Future of API Synthesis Look Like?

    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Bolsters Cell and Gene Services

    CDMO Sirio Pharma Completes the Acquisition of Best Formulations

    Meeting the Container Closure Integrity Requirements in the Revised EU Annex 1

    Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security

    Beat the Supply Chain Backlog
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Catalent Bolsters Cell and Gene Services

    Crown Bioscience to Acquire Indivumed’s Service Biz and Supporting Biobank

    Stevanato Group, Transcoject Partner on Pre-Fillable Syringe Polymer Options
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Adare Partners with Veeva to Strengthen Quality Operations

    KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva

    Enhancing Ease of Use, Batch Turnaround, and Process Flexibility

    Understanding the Essential Role of a Qualified Person

    Altasciences Los Angeles Clinical Site Receives CAP Accreditation
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Almac Group

    Bachem

    LOTTE BIOLOGICS

    Chiron Recombinant Proteins
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Almac Group

    Bachem

    LOTTE BIOLOGICS

    Chiron Recombinant Proteins
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Introducing ViroCell Biologics

    The UK’s first clinical trial focused viral vector manufacturer.

    Related CONTENT
    • Sekisui
    • Stiris Research Inc.
    • Jubilant HollisterStier
    • Thomas Scientific LLC
    • Lonza Further Invests in Drug Product Manufacturing Capabilities
    Charles Sternberg, Assistant Editor04.28.21
    ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).
     
    ViroCell aims to be the supplier of choice for viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials. ViroCell has assembled an experienced viral vector manufacturing team to support its heavy operational demand and is now building out further manufacturing capability to address the current, acute supply chain bottlenecks worldwide. ViroCell is deploying significant capital and management talent around the viral vector design and manufacturing track record of Farzin Farzaneh, PhD – professor of molecular medicine at King’s College London, and expects to employ more than 50 professionals in the UK by the end of 2021.
     
    Meeting the Demand for Viral Vectors in the UK
     
    The fast-growing demand in viral vectors for clinical trials makes clear the pressing need for a highly experienced commercial Contract Development and Manufacturing Organization (CDMO) that can leverage the best of the UK’s world-leading heritage by investing in new capacity, to design and deliver viral vectors for clinical trials faster and more reliably.
     
    The curative potential seen from the first wave of approved CGTs, is driving new company formation and external investment into therapies heading for clinical trial. The ViroCell team has contributed to innovative therapies to combat childhood inherited genetic diseases from muscular dystrophy to lysosomal storage disorders; and in adult acquired diseases from leukemia to solid tumors.
     
    ViroCell is negotiating with world-leading teaching hospitals and universities to bring more clean room facilities for the production of viral vectors in the UK.  The company, an innovation driven CDMO, founded in 2020 by the Truell Conservation Foundation and serial biotech entrepreneur, John W. Hadden II, has market leading cell and gene therapy expertise and decades of experience in oncology innovation through its world-class Scientific Advisory Board (SAB).

    SAB Chairman Ferid Murad, MD, PhD, co-winner of the 1998 Nobel Prize in Medicine, said, “I am delighted to chair this accomplished group and to help ViroCell innovate to support the advancement of the cell and gene therapy community.”
     
    In addition to Farzin Farzaneh and Ferid Murad, the SAB has embraced eminent leaders in the field:
     
    • Evren Alici, MD, PhD - Senior researcher and group leader in Hematology at Karolinska Institutet (KI), Department of Medicine, Stockholm, Sweden and co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies
    • Jean-Pierre Bizzari, MD – SAB member of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. He was formerly Executive Vice-President, Group Head, Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015
    • Mark Lowdell, PhD – Professor of Cell and Tissue Therapy at University College London and director of Cellular Therapy at the Royal Free London NHS Foundation Trust
    • Peter Harper, MD – Medical Oncologist, founder of the Oncology Department at Guy's and St Thomas' NHS Foundation Trust, the London Oncology Clinic, and Welbeck Health Partners
    • Paul G. Richardson, MD – Clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School
     
    Comments from Leadership
     
    Edmund Truell, chairman of the Truell Conservation Foundation, said, “We have been studying the viral vector supply-demand imbalance with great interest. We believe that the shortage of highly specialized design and manufacturing capacity and the UK’s hitherto uncommercial attitude to new vector innovation, represents a clear barrier to gene therapy innovation. Following the remarkable success of the UK Covid vaccine program and Kate Bingham’s galvanizing call to arms, this imbalance can now be changed for good.”
     
    Truell continued, “Prof. Farzaneh’s leadership in developing and manufacturing viral vectors will build on the excellent genetics research at the Wellcome Sanger Institute; King’s College London and other world-class centers of academic research; and our globally powerful pharmaceutical sector. We are delighted to capitalize and invest in ViroCell to accelerate the novel therapies that ViroCell’s clients are developing by enabling them to enter clinical trials faster and so help millions of patients.”
     
    John W. Hadden II, a longtime colleague of Truell and Farzaneh and co-founder of ViroCell, will lead the business as CEO while Prof. Farzaneh will lead vector design as chief scientific officer. Hadden commented, “It is exciting to join trusted partners to take Farzin’s vision and vector manufacturing leadership to the next level. Over the last 20 years, Farzin’s team has led the successful creation and manufacturing of over 100 viral vectors for dozens of CGT clinical trials around the world. With additional capital and the support of an experienced management structure, we look forward to extending and expanding on this tradition of life sciences innovation and leadership.”
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Sekisui Sekisui
    Stiris Research Inc. Stiris Research Inc.
    Jubilant HollisterStier Jubilant HollisterStier
    Thomas Scientific LLC Thomas Scientific LLC
    Lonza Further Invests in Drug Product Manufacturing Capabilities Lonza Further Invests in Drug Product Manufacturing Capabilities
    Rentschler Biopharma to Support Albert Einstein Discovery Center Rentschler Biopharma to Support Albert Einstein Discovery Center
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    Recro Pharma Signs Renewable Energy Agreement with Georgia Power Recro Pharma Signs Renewable Energy Agreement with Georgia Power
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    CuriRx Launches CuriLytics Platform for Biotherapeutic Development CuriRx Launches CuriLytics Platform for Biotherapeutic Development
    Thermo Fisher Launches Gibco AAV Production System Thermo Fisher Launches Gibco AAV Production System
    Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact
    Tevogen Completes Tech Transfer to CDMO BioCentriq Tevogen Completes Tech Transfer to CDMO BioCentriq
    BioVaxys Reports Progress on Covid-19 Vax Candidate BioVaxys Reports Progress on Covid-19 Vax Candidate

    Related Buyers Guide Companies

    • Sekisui

      ...
      Jim Alferman, Associate Director, Business Development 11.08.22

    • Stiris Research Inc.

      ...
      Denise Palmer, Manager, Business Development 11.04.22

    • Jubilant HollisterStier

      Jubilant HollisterStier

      Jubilant HollisterStier is an integrated contract manufacturer of sterile injectables, ophthalmics, otics and sterile and non-sterile topicals and liquids.
      04.22.22


    • Thomas Scientific LLC

      ...
      Carissa Gurgul, Conversion Rate Optimization Coordinator 10.28.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      Lonza Further Invests in Drug Product Manufacturing Capabilities

      Lonza Further Invests in Drug Product Manufacturing Capabilities

      New filling line to process various modalities, including monoclonal antibodies, bioconjugates, viral vectors, and other gene therapy products.
      09.22.21

    Loading, Please Wait..
    Trending
    • Sarepta And Catalent Expand Manufacturing Partnership
    • Forge Biologics Strengthens Genetic Medicine CDMO Capabilities
    • Colorcon Signs Agreement To Purchase Airnov Healthcare Packaging
    • The Ongoing Evolution And Implementation Of DCTs In 2023
    • EyePoint Pharmaceuticals To Build GMP Mfg. Facility In Northbridge, MA
    Breaking News
    • Pasithea Signs CMC Development and Manufacturing Agreement
    • Experic Expands Analytical Capabilities and Facilities
    • List Labs Expands Manufacturing Capacity
    • groninger Continues Growth in the US
    • Catalent Bolsters Cell and Gene Services
    View Breaking News >
    CURRENT ISSUE

    November/December 2022

    • Cold Chain Packaging and Logistics
    • Optimizing Supply Chains for Allogeneic Cell Therapy Trials
    • Sustainable Manufacturing
    • Bioprocessing Trends
    • How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Probiotics Supplementation Reduces Complications in Colorectal Cancer Patients
    Vitamin D Supplementation Reduces Risk of Dynapenia
    Sustained-Release Caffeine Ingredient Offers Mood, Performance Benefits
    Coatings World

    Latest Breaking News From Coatings World

    Epoxytec Announces New Website Launch
    Paints and Coatings Market Worth $212B by 2026: MarketsandMarkets
    Axalta Releases Fourth Quarter and Full Year 2022 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BMP Medical Expands Sterling, Massachusetts Facility
    Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy
    Environmental Sustainability Becoming Increasingly Important to Medtech Industry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pasithea Signs CMC Development and Manufacturing Agreement
    Experic Expands Analytical Capabilities and Facilities
    List Labs Expands Manufacturing Capacity
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Haircare Brand Uncle Funky’s Daughter Announces Retail Expansion
    TRESemmé Introduces New Pro Infusion Collection
    Walgreens Boots Alliance Shares 2022 ESG Report
    Happi

    Latest Breaking News From Happi

    KimChi Beauty Launches Spinning Hearts Love 02 Ahead of Valentine’s Day
    Dark & Lovely Names Actress Meagan Good Brand Ambassador
    Natural Household Care Company Tru Earth Adds Dishwasher Detergent Tablets
    Ink World

    Latest Breaking News From Ink World

    Xerox Releases 4Q, Full-Year 2022 Results
    Electronics For Imaging Names Frank Pennisi as CEO
    Fiery to Separate from EFI, Remain Wholly-Owned by Siris
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    EFI appoints Frank Pennisi CEO, Fiery now an independent business
    Bobst boosts senior sales team with Keith Nagle
    Penmar Industries adds Screen Truepress Jet L350UV SAI digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Essity’s Sales Grow
    Thinx to Pay up to $5 million to Settle Class Action Suit
    Typar Highlighting New Building Innovations
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Launches the Mariner Deformity System
    Tyber Medical Hires 2 New Execs
    Miach Ortho Raises $40M in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Smart Devices with Privacy Focus Have More Consumer Appeal
    Siman Group Partners with SML to Unlock Full Retail Potential with RFID
    Brewer Science Presents Optics Integration Solutions at SPIE Photonics West

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login